activated partial thromboplasitin time and
prothrombin time testing. Blood Coagul.
Fibrinolysis, 4(4), 635−638 (1993).
2. McManus, M. L., et al., Coagulation factor
deficiencies during initiation of extracorporeal
activated partial thromboplasitin time and
prothrombin time testing. Blood Coagul.
Fibrinolysis, 4(4), 635−638 (1993).
2. McManus, M. L., et al., Coagulation factor
deficiencies during initiation of extracorporeal
activated partial thromboplasitin time and
prothrombin time testing. Blood Coagul.
Fibrinolysis, 4(4), 635-638 (1993).
2. McManus, M. L., et al., Coagulation factor
deficiencies during initiation of extracorporeal
of p53 sequence specific DNA-binding
by covalent poly(ADP-ribosyl)ation. J. Biol. Chem.
July 26 (2001).
7. Pieper, A. A., et al., Poly(ADP-ribosyl)ation basally
activated by DNA strand breaks reflects
p53 sequence specific DNA-binding
by covalent poly(ADP-ribosyl)ation. J. Biol. Chem.
July 26 (2001).
7. Pieper, A. A., et al., Poly(ADP-ribosyl)ation basally
activated by DNA strand breaks reflects
. Preparation of a Cell-Free Protein-Synthesizing
System from Wheat Germ. Methods Enzymol. 101, 635 (1983).
2. Krieg, P.A. and Melton, D.A., Functional messenger RNAs are produced
by SP6 in vitro
Standard Methods 4500-NH3-F,G,H 1997 [3]
F. 640
G. 630-660
H. 630
USGS I-4523-85 [7] 630
Patton [6] 635-637
Krom [5] 630
EPA 350.1 [8]
660*
* Note: Method calls for
is 600/620 nm.
A range of 585 to 600 nm should be adequate. Monitoring of emission between 615 to
635 nm is in range. The optimal excitation/emission wavelength for a JOE-labeled
Amplifluor® SNP Primer
is 600/620 nm.
A range of 585 to 600 nm should be adequate. Monitoring of emission between 615 to
635 nm is in range. The optimal excitation/emission wavelength for a JOE-labeled
Amplifluor® SNP Primer
is 600/620 nm.
A range of 585 to 600 nm should be adequate. Monitoring of emission between 615 to
635 nm is in range. The optimal excitation/emission wavelength for a JOE-labeled
Amplifluor® SNP Primer
1.004 A P
635 nm 1.024 A 1.016 - 1.031 A 1.023 A P
Neutral Density 2.0 Abs.
Hellma 666-F203
440 nm 2.252 A 2.236 - 2.268 A 2.248 A P
546 nm 1.994 A 1.982 -
Jayasankar in Encyclopedia of Pharmaceutical Technology, Third Edition, Informa Healthcare, 2006, pp. 615–635.
[2] N. Upadhyay, T. P. Shukla, A. Mathur, J. S. K. Manmohan, Pharmaceutical Sciences Review and
y y
630 Raf-1 R5773 5894 RAF1 P NP_002871.1 y n/d y
634 RALAR R8529 5898 RALA M NP_005393.2 y y y
635 Ran R4777 5901 RAN M NP_006316.1 y y n/d
640 Retinoblastoma
y y
630 Raf-1 R5773 5894 RAF1 P NP_002871.1 y n/d y
634 RALAR R8529 5898 RALA M NP_005393.2 y y y
635 Ran R4777 5901 RAN M NP_006316.1 y y n/d
640 Retinoblastoma
y y
630 Raf-1 R5773 5894 RAF1 P NP_002871.1 y n/d y
634 RALAR R8529 5898 RALA M NP_005393.2 y y y
635 Ran R4777 5901 RAN M NP_006316.1 y y n/d
640 Retinoblastoma
y n/d n/d
634 RALAR R8529 5898, 56044, 81757 RALA,Rala NP_005393.2,NP_062364.3,NP_112355.1 M y y y
635 Ran R4777 5901, 19384 RAN,Ran NP_006316.1,NP_033417.1 M y y n/d
636 PIASy 51588, 59004, 362827
y n/d n/d
634 RALAR R8529 5898, 56044, 81757 RALA,Rala NP_005393.2,NP_062364.3,NP_112355.1 M y y y
635 Ran R4777 5901, 19384 RAN,Ran NP_006316.1,NP_033417.1 M y y n/d
636 PIASy P0104 51588, 59004